ClinicalTrials.gg
CompletedNCT04582656VIOLETTEUpdated Apr 6, 2026

Efficacy Assessment of a Novel 3D Cartography-based Targeted Focal Microwave Therapy in Men With Localized Intermediate-risk Prostate Cancer

An interventional study of Targeted microwave ablation in Prostate Cancer, sponsored by Koelis. Completed at 5 sites in 2 countries. Open to male participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Koelis · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Not applicable
Ages
45 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 509 studies in Prostatic Neoplasms with a site in France — 89 open to participants now, 154 under way, 50 of them phase 3. Prostatic Neoplasms · France.

Enrollment
287th of 405
76 · median 185
Started
2021
with 33 others
No phase
121 of 509
25 open now
Registered
341st of 509
by date

Among the 509 studies in Prostatic Neoplasms with a site in France, this one is the 287th largest by enrollment of the 405 interventional ones that give a count, is one of 34 that started in 2021, is one of 121 with no phase, and was the 341st registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

89 of the 509 studies in Prostatic Neoplasms with a site in France are open now. Recruiting first, the newest first:

84 more — sign in →

All 89 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 45 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 509 studies in Prostatic Neoplasms with a site in France, or all of them as a file.
02

Study summary

Multicenter, prospective, European, single-arm, open-label, 12-month follow-up clinical trial. The purpose of this study is to evaluate the efficacy of a 3D cartography-based targeted microwave ablation for the treatment of the index lesion in patients with intermediate risk prostate cancer.

Read the detailed description

European and American guidelines recommend several therapeutic alternatives: radical surgical treatment, external beam radiotherapy or brachytherapy. However, whole-gland treatment induces significant morbidity and burden on quality of life. Targeted treatments of the index tumor are currently under investigation to decrease morbidity while proposing active treatment.

The purpose of this study is to assess the efficacy of a novel ablation treatment using microwaves, delivered transrectally or transperineally under real-time guidance with MRI-transrectal ultrasound image registration. The index tumor will be detected with prostate MRI and characterized with targeted biopsies using Organ Based Tracking (OBT) fusion with the TRINITY system (KOELIS, Meylan, France). The same system will be used to identify the index lesion and guide the targeted microwave ablation performed with the TATO3 device (Biomedical Srl, Florence, Italy).

All patients will undergo biopsy at 12 months of follow-up. A biopsy session will also be performed at 6 months, but only for patients with imaging results suspicious for cancer within the ablated area on the mpMRI.

03

Conditions studied

  • Prostate Cancer

Keywords

  • Cancer
  • Prostate
  • Targeted treatment
  • Microwave
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient aged from 45 to 80 years old
  • >10 years at the inclusion time
  • Patient diagnosed with an intermediate-risk prostate cancer, defined by:

    • A T1c or T2a clinical stage
    • A unique cancer focus of Gleason (3+4) (Grade Group 2). In addition to the index lesion intended for treatment, the presence of additional microfoci \< 10mm on mpMRI, for which present no evidence of cancer or a Gleason score of 3+3, is accepted
    • A PSA level \<20 ng/mL
  • Cancer focus identified on a multiparametric MRI of the prostate no more than 3 months before inclusion
  • Confirmation of the suspicion of cancer identified on the MRI with transrectal or transperineal targeted and systematic biopsies performed with the KOELIS TRINITY system (no more than 3 months before inclusion)
  • Patient suitable for IV sedation or general anesthesia and focal microwave ablation
  • No debilitating medical or psychiatric illness that would preclude giving or receiving optimal treatment and follow-up
  • Known coagulopathy or bleeding disorders are controlled
  • Free, informed and written consent, dated and signed before the enrollment and before any exam required by the trial
  • Patient affiliated to social security regimen or beneficiary of such regimen for local regions

Exclusion criteria

Exclusion Criteria:

  • Past medical history of prostate surgery
  • Past medical history of radiotherapy or pelvic trauma
  • Past medical history of acute prostatitis
  • Presently taking hormonal manipulation or androgen supplements.
  • Past medical history of cancer in the 5 previous years, excluding a non- basal cell carcinoma of the skin
  • Severe BPH-related urinary tract symptoms, defined by an IPSS score >18
  • Serious medical illness, including any of the following: uncontrolled congestive heart failure, uncontrolled angina, myocardial infarction, cerebrovascular event within 6 months prior to the screening visit
  • for MRI exam
  • Extracapsular cancer extension or seminal vesicles or pelvic lymph node invasion suspected on prostate MRI
  • Presence of two or more cancer foci in the inclusion exam
  • Presence of a clinically significant cancer with a Gleason score ≥8 (Grade Group ≥4)
  • Tumor largest axis >15 mm on the prostate MRI
  • Distance between the cancer focus and the apex \<5 mm on the prostate MRI
  • Distance between the cancer focus and the rectum \<5 mm on the prostate MRI
  • Patient already participating in an interventional clinical trial
  • Patient protected by law
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Targeted microwave ablation

    Targeted microwave transrectal or transperineal ablation of the prostatic index tumor using MRI-transrectal image registration and OBT fusion

    Device: Targeted microwave ablation

Interventions

  • DeviceTargeted microwave ablation

    Targeted ablation of the index tumor with microwaves, by using either a transperineal or a transrectal approach

06

What researchers measure

Primary outcomes

  1. The proportion of patients with no evidence of cancer on targeted biopsy

    The proportion of patients with no evidence of cancer on targeted biopsy at 12 months, defined by a minimum of 2 targeted core biopsies taken from the index tumor site treated with microwave ablation for focal treatment of intermediate risk prostate cancer

    Time frame: 12 months

Secondary outcomes

  1. Proportion of radical salvage treatment

    Proportion of patients undergoing radical salvage treatment of the index lesion

    Time frame: 12 months

  2. Time to radical salvage treatment

    Time to radical salvage treatment of the index lesion

    Time frame: 12 months

  3. Proportion of patients with any cancer in the untreated area

    Proportion of patients with any cancer in the untreated area, determined by a minimum 12 cores systematic biopsy

    Time frame: 12 months

  4. Proportion of patients undergoing treatment for cancer in the untreated area

    Proportion of patients undergoing treatment for cancer in the untreated area and time to treatment

    Time frame: 12 months

  5. IPSS questionnaire

    Changes in patients' reported outcome measures (PROMs) for urinary symptoms using IPSS score compared to baseline, score ranging from 0 to 35 (the higher the worse)

    Time frame: 7 days and 1, 6 and 12 months

  6. IIEF-5 questionnaire

    Changes in patients' reported outcome measures (PROMs) for erectile function using IIEF-5 score compared to baseline, score ranging from 5 to 25 (the lower the worse)

    Time frame: 7 days and 1, 6 and 12 months

  7. MSHQ-EjD-SF questionnaire

    Changes in patients' reported outcome measures (PROMs) for ejaculatory function and bother using MSHQ-EjD-SF score compared to baseline, score ranging from 1 to 15 (the lower the worse) for ejaculatory function and from 0 to 5 for bother/satisfaction (the higher the worse)

    Time frame: 7 days and 1, 6 and 12 months

  8. Urine flow

    Change in urine flow, using a uroflowmeter compared to baseline

    Time frame: 7 days and 1, 6 and 12 months

  9. Adverse events

    Number and severity of device and procedure related adverse events

    Time frame: 12 months

  10. Patient post-operative pain level

    Average patient post-operative pain level reported on a pain numeric rating scale, with a range from 0 (no pain) to 10 (worst pain ever)

    Time frame: Treatment day-evaluated between 2 and 4 hours after the procedure

  11. Patient satisfaction

    Patient satisfaction with the microwave ablation procedure as determined by questionnaire (no score assigned)

    Time frame: 1, 6 and 12 months

  12. Ease of the procedure

    Ease of the procedure measured with a score chosen by the operator (1: easy, 2: moderate, 3: difficult)

    Time frame: Day 1

  13. Duration of the procedure and associated variables

    Duration of the procedure and associated variables

    Time frame: Day 1

  14. PSA

    Change in PSA measurement compared to baseline

    Time frame: 1, 3, 6, 9 and 12 months

  15. PSA Nadir

    Time to PSA Nadir after treatment of the index lesion

    Time frame: 12 months

  16. Prostate volume

    Change in volume of the prostate on the mpMRI compared to baseline

    Time frame: 7 days and 6 and 12 months

  17. Patient motivation

    Characterization of patient motivation to undergo targeted microwave ablation for treatment of the index lesion, as assessed by patient questionnaire (no score assigned)

    Time frame: Baseline

  18. Surgeon opinion regarding adequate guidance of the microwave ablation needle

    To evaluate the adequate guidance of the microwave ablation needle by the surgeon opinion

    Time frame: Day 1

  19. Adequate guidance of the microwave ablation needle on the treated index lesion

    To evaluate the adequate guidance of the microwave ablation needle by percentage of covering of the treated index lesion

    Time frame: Day 1

  20. Adequate guidance of the microwave ablation needle on the treated index lesion and margins

    To evaluate the adequate guidance of the microwave ablation needle by percentage of covering of the treated index lesion and margins

    Time frame: Day 1

  21. Learning curve of the TMA procedure

    To evaluate the learning curve of the TMA procedure by the duration of the intervention (delay between probe in and the end of anesthesia (minutes).

    Time frame: Day 1

07

Study locations

5 sites
  • Institut Jules Bordet
    Brussels, 1000, Belgium
  • Centre Hospitalier Universitaire de Bordeaux
    Bordeaux, 33000, France
  • American Hospital of Paris
    Neuilly-sur-Seine, 92200, France
  • Hôpital Cochin (Assistance Publique - Hôpitaux de Paris)
    Paris, 75014, France
  • Urologie Nantes Clinique & Institut d'Urologie - Site Atlantis
    Saint-Herblain, 44800, France
08

References and documents

Publications

  • Delongchamps NB, Peltier A, Potiron E, Bladou F, Diamand R, Messas A, Roche JB, Robert G, Hoepffner JL, Piechaud T, Anract J, Velthoven RV. Targeted microwave ablation of localised prostate cancer (VIOLETTE trial): a prospective multicentre study. BJU Int. 2026 Jun;137(6):1032-1039. doi: 10.1111/bju.70220. Epub 2026 Mar 11. PubMed 41810596 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Jul 2025, 53 months.

Of 58 industry-sponsored interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 72. This study's 53 months is above that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2020
First posted
Oct 9, 2020
StartActual
Feb 11, 2021
Primary completionActual
Jul 29, 2025
CompletionActual
Aug 21, 2025
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04582656
Lead sponsor
Koelis
Responsible party
Sponsor
First posted
Oct 9, 2020
Start date
Feb 11, 2021
Primary completion
Jul 29, 2025
Completion
Aug 21, 2025
Last update
Apr 6, 2026

Study contacts

Roland VAN VELTHOVEN, MD
study chair · Uro Science & Consulting

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion